Moderna, Inc. (MRNA) FY2025 Annual P&L / Income Statement

Moderna, Inc. (MRNA) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

1,944,000,000 US dollars

Cost of sales

868,000,000 US dollars

Gross profit (calculated)

1,076,000,000 US dollars

Operating expenses (calculated)

4,150,000,000 US dollars

Loss from operations

negative 3,074,000,000 US dollars

Other income (expense), net (calculated)

306,000,000 US dollars

Loss before income taxes

negative 2,768,000,000 US dollars

Provision for (benefit from) tax provision

54,000,000 US dollars

Net loss

negative 2,822,000,000 US dollars

COVID-19

1,810,000,000 US dollars

RSV

8,000,000 US dollars

Net product sales - UNITED STATES

1,165,000,000 US dollars

Net product sales - Rest of world

603,000,000 US dollars

Net product sales - Europe

50,000,000 US dollars

Research and development

3,132,000,000 US dollars

Selling, general and administrative

1,018,000,000 US dollars

Revenue before reconciliation (calculated)

3,636,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Components above reported revenue (calculated)

negative 1,692,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.